Cantargia investor relations material

Listen to the latest call from Cantargia

Cantargia AB, a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. Its lead product is CAN04, an antibody directed the interleukin-1 receptor accessory protein that targets cancer cells that express IL1RAP on their surface; and CAN04 is currently being developed in two clinical programs, one focusing on treatment of lung cancer and another on treatment of pancreatic cancer. Cantargia AB was founded in 2010 and is based in Lund, Sweden.

Dig deeper into the Cantargia fundamentals on Quartr.